Skip to main contentSkip to footer

Yesterday, Oona Reardon had the pleasure of moderating a panel at the LifeSciences Australia Summit at the Museum of Sydney: HTA Reform Across Medicines,

Yesterday, Oona Reardon had the pleasure of moderating a panel at the LifeSciences Australia Summit at the Museum of Sydney: HTA Reform Across Medicines, Generics and MedTech.

She was joined by Elizabeth de Somer (Medicines Australia), Warren Bingham (MedTech International) and Sylvain Vigneault (Viatris) to tackle a question that doesn't have an easy answer: does one HTA reform agenda work equally well across medicines, generics and MedTech?

Some of the themes that stood out:

– Structured, conditional access pathways (with real-world evidence collection) offer a practical middle ground between waiting years for certainty and taking on unmanaged risk.

– Delay to reimbursement shapes whether Australia gets prioritised for global launch and whether local manufacturing and innovations stay here or move offshore.

– Savings generated through generics and biosimilar competition need to be visibly reinvested if they're going to fund the next wave of innovation.

The summit also featured a session moderated by Anne O'Neill FTSE PSM with Andrew Wilson (former PBAC Chair) and Kate Mahon (PBAC/ESC member) unpacking what PBAC is actually looking for in a strong submission, a timely reminder that reform conversations and day-to-day submission practice need to move together.

#HTAReform #MarketAccess #HealthEconomics #PBAC #MedTech #PulseEconomics #patientcentricity Tim Boyle Anna Megalakakis

Read the LinkedIn post

Previous Post
I’ll be attending this year’s AusBiotech International Conference & AusMedtech Conference on the Gold Coast, October 21-23.
Next Post
ANDHealth Deep Dive: digital health, AI and the future of care